WCM Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$576M Buy
1,152,094
+30,753
+3% +$13.6M 1.04% 34
2026
Q1
$497M Sell
1,121,341
-7,804
-0.7% -$3.64M 1.13% 35
2025
Q4
$512M Sell
1,129,145
-20,987
-2% -$9.05M 1.05% 36
2025
Q3
$455M Sell
1,150,132
-13,538
-1% -$5.66M 0.95% 32
2025
Q2
$514M Buy
1,163,670
+64,730
+6% +$29.8M 1.17% 30
2025
Q1
$541M Buy
1,098,940
+7,418
+0.7% +$3.46M 1.39% 30
2024
Q4
$436M Buy
+1,091,522
New +$506M 1.03% 36

Other funds holding VRTX

WCM Investment Management's VRTX Position: Q2 2026 in Review

WCM Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q2 2026, buying an estimated $13.6M and bringing the position to 1,152,094 shares worth $576M. The position accounts for 1.04% of the portfolio, ranked #34.

WCM Investment Management first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • WCM Investment Management held 1,152,094 shares of Vertex Pharmaceuticals worth $576M as of Q2 2026.
  • WCM Investment Management bought 30,753 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.6M.
  • Vertex Pharmaceuticals made up 1.04% of WCM Investment Management's portfolio in Q2 2026, its #34 holding.
  • WCM Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on WCM Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.